ASBM Promotes High Approval Standards, Memorable Names at DIA 2016

ASBM was an exhibitor during the 52nd Annual meeting of the Drug Information Association (DIA) held June 26th-30th in Philadelphia.

ASBM members and staff discussed biosimilars policy with attendees, including the need for the FDA to maintain high standards for safety and efficacy when approving biosimilars.

More than 65 attendees, including clinical researchers, physicians, pharmacists, patients, and regulators, filled out “Names Matter” postcards urging the FDA to adopt meaningful, memorable suffixes in future biosimilar approvals (as it did in its first approval) rather than random suffixes (as it did in its second).

IMG_8420 5
ASBM’s booth at DIA 2016

 

IMG_8416 3
ASBM’s Executive Director, Michael Reilly was in attendance and discussed biosimilar policy with other conference attendees.

 

 

IMG_8387 2
DIA 2016 attendees filled out postcards urging the FDA to adopt meaningful, memorable suffixes for biosimilars.

 

IMG_8390
John Lewis, VP of Communications for the Association of Clinical Research Organizations (ACRO), fills out a postcard.

 

 

IMG_8381
ASBM also promoted the benefits of meaningful, memorable biologic naming through multiple table advertisements in the refreshment area.